Wealth Enhancement Advisory Services LLC Purchases 1,512 Shares of Smith & Nephew SNATS, Inc. $SNN

Wealth Enhancement Advisory Services LLC grew its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 4.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,077 shares of the medical equipment provider’s stock after buying an additional 1,512 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Smith & Nephew SNATS were worth $1,092,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Hexagon Capital Partners LLC lifted its position in shares of Smith & Nephew SNATS by 63.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 406 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Smith & Nephew SNATS by 15.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider’s stock valued at $118,000 after buying an additional 541 shares in the last quarter. Gallacher Capital Management LLC lifted its position in shares of Smith & Nephew SNATS by 6.4% during the 2nd quarter. Gallacher Capital Management LLC now owns 10,622 shares of the medical equipment provider’s stock valued at $325,000 after buying an additional 639 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Smith & Nephew SNATS by 22.4% during the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider’s stock valued at $103,000 after buying an additional 666 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Smith & Nephew SNATS by 4.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 15,281 shares of the medical equipment provider’s stock worth $434,000 after purchasing an additional 672 shares in the last quarter. 25.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on SNN. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 30th. Canaccord Genuity Group boosted their price target on Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, August 18th. Six research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $36.00.

Smith & Nephew SNATS Stock Performance

NYSE:SNN opened at $36.81 on Thursday. The stock’s fifty day moving average is $35.97 and its 200 day moving average is $31.09. Smith & Nephew SNATS, Inc. has a fifty-two week low of $23.69 and a fifty-two week high of $38.79. The firm has a market capitalization of $16.03 billion, a PE ratio of 17.04, a PEG ratio of 1.00 and a beta of 0.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.

Smith & Nephew SNATS Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be given a $0.285 dividend. This represents a yield of 210.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS’s dividend payout ratio is 41.20%.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.